Migränerton (Paracetamol, Metoclopramide Hydrochloride Monohydrate)

Paracetamol reduces headache pain by centrally inhibiting cyclo‑oxygenase enzymes and lowering prostaglandin production. Metoclopramide blocks dopamine D2 receptors, which speeds gastric emptying, reduces nausea, and adds a modest analgesic effect through central nervous system pathways.

The specific dose and dosing schedule of Migränerton are determined by the prescribing clinician based on the patient’s condition, severity of symptoms, and individual health factors. Patients should follow the prescriber’s instructions exactly.

Safety data for Migränerton in pregnancy and lactation are limited. Healthcare providers should weigh potential benefits against possible risks and consider alternative therapies when appropriate. Women who are pregnant or nursing should discuss use with their physician.

To request Migränerton, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Migränerton offers a dual mechanism—analgesic and anti‑emetic—in a single tablet, which can be advantageous over single‑agent therapies that address only pain or nausea. Compared with triptans, it may be used when triptans are contraindicated, but it does not have the vasoconstrictive properties of triptans.

Store Migränerton at ambient temperature, preferably below 25 °C. Keep the tablets in the original container, protect them from moisture, heat and direct sunlight, and ensure they are out of reach of children.

Migränerton is taken orally, usually with a glass of water. It can be taken with or without food, but patients should follow the prescriber’s guidance on timing relative to meals to optimize absorption and reduce gastrointestinal discomfort.

Serious risks include rare extrapyramidal reactions such as dystonia, neuroleptic malignant syndrome, severe allergic reactions, and potential liver injury from paracetamol overdose. Patients should seek immediate medical attention if they experience muscle rigidity, high fever, rash, or signs of liver dysfunction.

Migränerton should be avoided in individuals with known hypersensitivity to paracetamol, metoclopramide, or any excipients, as well as in patients with severe hepatic impairment, uncontrolled epilepsy, or those taking MAO inhibitors. A healthcare professional should evaluate suitability before prescribing.